Clarity Pharmaceuticals’ Post

Since 2017, the field of radiopharmaceuticals in the United States has shown remarkable growth. The market size has surged from $63 million initially to $408 million by 2023, representing a staggering growth rate of 550%. This figure reflects the industry's broad recognition of future potential and the market's high attention to this technology direction.   In this booming market environment, on November 29, 2022, Full-Life Technologies announced the acquisition of Focus-X Therapeutics for US$245 million, which not only reflects Full-Life Technologies’ leadership in the field of nuclear medicine The strategic decision also emphasizes Focus-X's peptide research and development capabilities, strengthening the company's globalization strategy and competitive position in the peptide field.   The development trends in the field of radiopharmaceuticals and the strategic layout of Full-Life Technologies illustrate the market prospects in the field of nuclear medicines. As a Sino-foreign joint venture in nuclear medicine research, PanMediso Holdings has a deep understanding of nuclear medicines. The future development prospects of nuclear medicine will be based on the development opportunities of the market, and through independent research and development and the introduction of international cutting-edge technologies, we will strive to improve the research and development level of nuclear medicine and provide patients with more advanced and personalized treatment solutions. #isotope #nuclearmedicine

Nuclear Medicine Market worth $9.4 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/d7TedHwf The global #nuclearmedicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. #radiopharmaceuticals 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲: Use of radiopharmaceuticals in neurological applications GE HealthCare Cardinal Health Curium Pharma Bayer Lantheus Bracco PharmaLogic Holdings Corp. Eczacıbaşı-Monrol Nuclear Products NTP Radioisotopes SOC Ltd. (A SUBSIDIARY OF @SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) Nordion Advanced Accelerator Applications (A Novartis COMPANY) NorthStar Medical Radioisotopes, LLC Eckert & Ziegler AG Siemens Healthineers JUBILANT DRAXIMAGE RADIOPHARMACIES INC. Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd. BWXT Medical Ltd. Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd Cyclopharm IRE ELiT - Radiopharma

Voximetry has teamed with Flywheel to ensure the secure transfer of clinical imaging data while simplifying the de-identification of protected health information for nuclear medicine radiopharmaceutical therapy clinics. This combined solution makes the process for clinics to receive remote dosimetry services is as simple as “Upload. Download. Done.”

Nuclear Medicine Market worth $9.4 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dQihBbJM The global #nuclearmedicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. #radiopharmaceuticals 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲: Use of radiopharmaceuticals in neurological applications GE HealthCare Cardinal Health Curium Pharma Bayer Lantheus Bracco PharmaLogic Holdings Corp. Eczacıbaşı-Monrol Nuclear Products NTP Radioisotopes SOC Ltd. (A SUBSIDIARY OF @SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) Nordion Advanced Accelerator Applications (A Novartis COMPANY) NorthStar Medical Radioisotopes, LLC Eckert & Ziegler AG Siemens Healthineers JUBILANT DRAXIMAGE RADIOPHARMACIES INC. Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd. BWXT Medical Ltd. Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd Cyclopharm IRE ELiT - Radiopharma

The specific activity of a radionuclide refers to the activity per unit mass of a radioactive substance. It is a measure of the amount of radioactivity that is present in a given quantity of a material. The specific activity is usually expressed in units of becquerels per gram (Bq/g) or curies per gram (Ci/g). The activity of a radionuclide is determined by its decay rate, which is characteristic of each radioactive isotope. This decay rate is defined by the half-life of the isotope, which is the time it takes for half of the atoms in a sample to decay. Radionuclides with shorter half-lives have higher specific activities because they decay more rapidly, releasing their radiation in a shorter period of time. The specific activity can be important in various fields, such as in nuclear medicine, where it helps in determining the appropriate dose of a radioactive drug, and in environmental monitoring, where it helps in assessing the level of contamination by radioactive substances. #radiopharmaceuticals #nuclearmedicine

PanMediso Holdings has been committed to promoting the research and innovation of isotope nuclear medicine, and continues to pay attention to and support innovative development in the industry. Recently, news about isotope-related innovations has attracted strong attention in the field of nuclear medicine. 1.[ARTBIO announced the completion of an excess Series A financing of more than US$90 million. F-Prime Capital and Omega Funds, the leading institutions in the seed round, also significantly participated in this financing. ] 2.[Ractigen Therapeutics’ RAG-01 became the second saRNA drug in the world to enter the clinical stage and the first saRNA drug in China to achieve this milestone. ] 3. [Lepu Biopharma's independently developed EGFR-targeted ADC product MRG003 has been granted fast track status by the FDA, providing new hope for the treatment of advanced nasopharyngeal cancer (NPC). ] 4. [CARsgen's CT071 received IND approval from the FDA and became a CAR-T cell product candidate for relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia. ] 5. [China National Nuclear Corporation successfully independently developed kilogram-level 99% abundance molybdenum-100 isotope, achieving independent supply of key molybdenum isotope materials in China]   PanMediso Holdings keenly grasped that this is a clear signal that the field of isotope nuclear medicine is ushering in a new round of high attention. By continuing to pay attention to market needs, we strive to find and promote more forward-looking innovation opportunities to meet patient and market needs. #isotope #nuclearmedicine

📰 PLAMORF PREPRINT! Systemic mRNA transport depends on m5C methylation, nuclear mRNA export factors and developmental phase changes https://lnkd.in/dXYuchCj #mRNA #plantscience #methylation #development #flowering #grafting

🎉 We just 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 for our Ge-68/Ga-68 radionuclide generator, 𝗚𝗮𝗹𝗹𝗶𝗮𝗣𝗵𝗮𝗿𝗺® from the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻. This approval extends our reach to an additional 14 countries in the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗔𝗿𝗲𝗮 (EEA), making GalliaPharm® the 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗹𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗚𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿 across the entire EEA once national approvals are secured.🌐 💬 “Over the past decade, diagnostics with 𝗴𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴-𝗯𝗮𝘀𝗲𝗱 𝗱𝗿𝘂𝗴s have experienced a 𝗵𝘂𝗴𝗲 𝗴𝗿𝗼𝘄𝘁𝗵, which we were able to actively influence with our GalliaPharm®,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “We are happy that our continued efforts to shape the landscape of nuclear medicine in Europe and around the world, are 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗮𝗻𝗱 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿𝘄𝗮𝗿𝗱.” ⚛️ Radionuclide generators offer a 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗳𝗹𝗲𝘅𝗶𝗯𝗹𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 for nuclear medicine clinics, enabling the radiolabeling of biomolecules used in positron emission tomography (PET) 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻. This is a major step forward in diagnostics for prostate and neuroendocrine tumors as well as future applications, 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗰𝗼𝘀𝘁𝘀 𝗮𝗻𝗱 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 for patients and healthcare providers. 🏥 🔗 Read more in the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, link in the comments ⬇️ #ContributingToSavingLives #NuclearMedicine #Radiopharmaceuticals #Gallium68

#OurPartners Actinium-225 is key to many new cancer therapies. However, global supply is severely restricted and the amount produced is insufficient to meet patients’ needs. To address this shortfall, Canadian Nuclear Laboratories is increasing production through a new Ac-225 development project which will help give the world access to promising cancer therapies. https://lnkd.in/g4WCAgi5

Nuclear Medicine Market Worth $9.4 Billion by 2028 ☑️𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:https://lnkd.in/dZmHWKnn The size of global nuclear medicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. 🔵𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 GE HealthCare Cardinal Health Curium Pharma Bayer Lantheus Bracco Imaging Korea Eczacıbaşı-Monrol Nuclear Products NTP Radioisotopes SOC Ltd Nordion Advanced Accelerator Applications NorthStar Medical Radioisotopes, LLC Eckert & Ziegler SE Siemens Healthineers Jubilant DraxImage, Inc. Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd BWXT Medical Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd Cyclopharm